The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

More evidence of the risks of Vioxx was presented by studies recently published online in the Journal of the American Medical Association. The studies produced added information about increased cardiovascular and renal risks with the use of Vioxx. According to the authors of one of the studies, the cardiovascular risks of Vioxx occur at both low and high doses. In addition to the Vioxx risks, the recent studies also found an increased risk with Celebrex doses over 200 mg per day. Concerns were also raised about the cardiovascular safety of diclofenac, which is a non-steroidal anti-inflammatory drug (NSAID). Vioxx was taken off the market in 2004 when Merck disclosed information that long-term use, of at least 18 months, of Vioxx increased the risk of cardiovascular events. Following additional analysis, Merck announced that the increased risk occurred earlier than 18 months.

Comments are closed.

Of Interest